Advaxis Inc. (NASDAQ:ADXS) dropped 5.2% on Tuesday . The company traded as low as $13.33 and last traded at $13.45, with a volume of 969,526 shares trading hands. The stock had previously closed at $14.19.

ADXS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Advaxis in a research report on Friday, August 5th. Jefferies Group reissued a “buy” rating on shares of Advaxis in a research report on Thursday, August 4th. FBR & Co reissued an “outperform” rating and issued a $34.00 price target on shares of Advaxis in a research report on Tuesday, May 17th. Finally, Barclays PLC boosted their price target on shares of Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, August 3rd. Six equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $25.80.

The firm’s market capitalization is $458.52 million. The company’s 50 day moving average price is $10.68 and its 200 day moving average price is $8.75.

In related news, Director David Sidransky sold 22,808 shares of Advaxis stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total value of $342,348.08. Following the sale, the director now directly owns 91,759 shares in the company, valued at approximately $1,377,302.59. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard J. Berman sold 18,000 shares of Advaxis stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $15.21, for a total transaction of $273,780.00. Following the completion of the sale, the director now owns 66,430 shares in the company, valued at $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.